A phase I study evaluated the safety, tolerability, and pharmacokinetics of PF-06647020 in patients with advanced solid tumors. The study involved dose escalation and expansion to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). PF-06647020 was administered intravenously every 3 weeks or every 2 weeks, with the RP2D established at 2.8 mg/kg every 3 weeks. The study also assessed the drug's antitumor activity and immunogenicity, with a focus on patients with advanced ovarian cancer, NSCLC, and TNBC.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.